HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

SIMPLE SUMMARY: Neoadjuvant treatment with anti-HER2 drugs such as trastuzumab or pertuzumab improves outcomes in patients with HER2-positive breast cancer. However, resistance to this treatment in some patients determines a need to identify genetic biomarkers able to predict patient responses and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Novillo, Apolonia, Gaibar, María, Romero-Lorca, Alicia, Malón, Diego, Antón, Beatriz, Moreno, Amalia, Fernández-Santander, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913086/
https://www.ncbi.nlm.nih.gov/pubmed/36765720
http://dx.doi.org/10.3390/cancers15030763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913086/
https://www.ncbi.nlm.nih.gov/pubmed/36765720
http://dx.doi.org/10.3390/cancers15030763

Ejemplares similares